Donor-Derived Cell-Free DNA Emerges as Leading Biomarker in Kidney Transplant Rejection Surveillance, Market to Reach $3.98 Billion by 2036
核心洞察
The global kidney transplant rejection (搜索) biomarker market is projected to grow from USD 1,362.8 million in 2026 to USD 3,975.3 million by 2036 at an 11.3% CAGR, driven by increasing adoption of non-invasive liquid biopsy testing.
Donor-derived cell-free DNA (dd-cfDNA) (搜索) is expected to hold 31.1% of the biomarker type segment in 2026, supported by blood-based sampling and measurable graft-derived injury signals across repeat surveillance visits.
A June 2024 Nature Medicine study covering 2,882 recipients across 14 centers has built confidence for liquid biopsy use in kidney transplant surveillance, accelerating clinical adoption.
The global kidney transplant rejection (搜索) biomarker market is poised for substantial expansion, with valuation expected to climb from USD 1,362.8 million in 2026 to USD 3,975.3 million by 2036, reflecting an 11.3% compound annual growth rate, according to a comprehensive analysis by Future Market Insights. The growth trajectory is underpinned by mounting clinical evidence supporting non-invasive liquid biopsy approaches and an expanding global recipient base that demands structured graft surveillance.
A February 2026 transplantation report documented 110,467 kidney transplants across 90 countries during 2024, illustrating the substantial recipient population requiring ongoing monitoring. This demographic pressure, combined with physicians' increasing reliance on regular blood and urine tests to detect graft injury early, is reshaping the diagnostic landscape for transplant medicine.
Donor-Derived Cell-Free DNA Takes Center Stage
Among biomarker types, donor-derived cell-free DNA (dd-cfDNA) (搜索) is projected to represent 31.1% of the market share in 2026, positioning it as the dominant modality. Blood-based sampling reduces dependence on scheduled tissue collection during routine follow-up, while serial readings help clinicians distinguish stable patterns from changes requiring closer review.
A meta-analysis published in Biomolecules and Biomedicine in February 2024 reported a pooled AUROC of 0.80 for any rejection using dd-cfDNA, reinforcing its clinical utility. "Clinical interpretation is expected to position dd-cfDNA beside biopsy and standard monitoring during uncertain graft-injury assessment," the FMI report notes.
The landmark study published in Nature Medicine in June 2024, covering 2,882 recipients across 14 centers, has been pivotal in building confidence for liquid biopsy use during specialist kidney-transplant surveillance. This comprehensive dataset is expected to accelerate clinical adoption of non-invasive diagnostic tools across hospitals worldwide.
Next-Generation Sequencing Dominates Technology Landscape
Next-generation sequencing (NGS) is estimated to secure 33.2% of the technology segment in 2026, guided by scalable donor-recipient discrimination and standardized processing across repeated post-transplant samples. A March 2024 American Journal of Transplantation study evaluated 151 kidney-transplant recipients through an NGS blood RNA signature, supporting advanced molecular readouts within genomics workflows.
PCR/qPCR and digital PCR (dPCR) promote targeted quantification across laboratories using real-time PCR systems, while ELISA and microarray address protein measurement and expression profiling for multiplex discovery applications.
Acute Rejection Detection Drives Application Demand
By application, acute rejection detection is anticipated to hold 34.0% of the market share in 2026, reflecting urgent therapy decisions prompted by suspected graft injury and uncertain creatinine changes. An analysis published in the American Journal of Kidney Diseases in April 2024, covering 1,559 biopsy-paired urine samples, highlighted noninvasive rejection assessment across surveillance and graft-dysfunction episodes.
The ExoTRU study, published in Kidney International Reports in February 2025, demonstrated 94% sensitivity for acute rejection, supporting noninvasive triage prior to selected biopsy decisions. However, the November 2024 EU-TRAIN study in Kidney International, which assessed 412 patients, found limited added discrimination from evaluated biomarkers beyond established clinical variables, suggesting that mixed incremental value may constrain adoption for panels lacking reproducible action thresholds.
Transplant Centers Lead End-User Adoption
Transplant centers are forecast to account for 44.0% of end-user share in 2026, driven by direct control over surveillance schedules and immunosuppression decisions. An August 2025 analysis published in the American Journal of Transplantation, covering 1,743 kidney-transplant recipients, connected dd-cfDNA levels with rejection yield across surveillance and for-cause settings, providing real-world evidence supporting specialist interpretation.
Regional Growth Dynamics
Japan leads country-level growth projections at 13.7% CAGR, supported by concentrated specialist institutions and structured post-transplant follow-up. The Statistics Bureau of Japan placed the population aged 65 years or older at 36.243 million in its April 2025 publication, increasing clinical pressure for durable graft monitoring among older recipients.
The United Kingdom follows at 12.1% CAGR, with NHS Blood and Transplant reporting more than 6,500 people on the kidney waiting list as of November 2025. The United States is projected to advance at 11.1% CAGR, supported by the Scientific Registry of Transplant Recipients' count of 27,660 kidney transplants during 2024. Germany and South Korea round out the comparison at 10.0% and 9.2% CAGR, respectively.
Competitive Landscape and Key Developments
CareDx and Natera are positioned as leading competitors in dd-cfDNA monitoring, with both companies receiving direct assay review across kidney-transplant surveillance programs. In February 2025, CareDx announced European validation of AlloSeq cfDNA involving 580 kidney-transplant patients. In July 2025, Natera announced PEDAL study results involving 488 kidney-transplant recipients, supporting longitudinal Prospera assessment following biopsy-proven rejection episodes.
Verici Dx (搜索) and Insight Molecular Diagnostics are adding transplant-specific gene-expression and dd-cfDNA options. In June 2026, Verici Dx received New York State approval for its Tutivia kidney-transplant rejection test, expanding nationwide clinical access for gene-expression risk assessment.
Eurofins Scientific SE (搜索) and Bio-Rad Laboratories (搜索) are anticipated to support laboratory access and molecular measurement requirements, while Thermo Fisher Scientific (搜索) provides broader molecular platform infrastructure.
Clinical Evidence and Market Restraints
Despite strong growth drivers, the market faces notable restraints. Biomarker elevation may reflect infection or non-rejection injury across complex post-transplant cases, and variable thresholds reduce confidence if results lack a clearly defined clinical response. The EU-TRAIN study's findings underscore that uncertain interpretation standards may delay sourcing as clinicians require consistent evidence before changing established surveillance protocols.
Anurag Sharma, Principal Consultant for Healthcare at Future Market Insights, noted: "Kidney rejection biomarkers create durable value as measured signals alter biopsy timing and therapy review within repeatable specialist pathways. Company progress is anticipated to reflect laboratory consistency and clinical education across transplant programs."
The market opportunity lies in serial multimarker services supporting longitudinal surveillance and integrated reports combining molecular trends with clinical history to improve specialist interpretation across repeat visits. Wider integration with electronic records could create opportunities for personalized monitoring schedules and earlier immunosuppressive treatment adjustments.